Skip to content
Peptigraph home

Ecnoglutide Phase 3 trial (NCT05680155)

A Phase 3, Multi-center, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of XW003 in Patients With T2DM Inadequately Controlled by Diet and Exercise Alone

Registry record checked

At a glance

Phase
Phase 3
Status
Completed
Enrolment
211
actual
Start
29 Dec 2022 (actual)
Primary completion
12 Jun 2024 (actual)
Sponsor
Hangzhou Sciwind Biosciences Co., Ltd.
Design

Arms and doses

NCT05680155 study arms
ArmTypeInterventionsDescription
C1-XW003ExperimentalDrug: EcnoglutideHigh dosage of XW003 once weekly
C1-PlaceboPlacebo comparatorDrug: PlaceboMatched Placebo once weekly
C2-XW003ExperimentalDrug: EcnoglutideLow dosage of XW003 once weekly
C2-PlaceboPlacebo comparatorDrug: PlaceboMatched Placebo once weekly
Endpoints

Primary endpoint

NCT05680155 primary outcomes
MeasureTime frame
Change from baseline in HbA1cBaseline, Week 24
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT05680155 secondary outcomes
MeasureTime frame
Change from baseline in HbA1cBaseline, Week 5, Week 9, Week 13, Week 17, Week 29, Week 33, Week 37, Week 45, Week 52
Proportion of subjects with HbA1c < 7% and HbA1c ≤6.5% after treatmentweek 24, week 52
Proportion of subjects with HbA1c < 7%, with no severe hypoglycemia or no weight gainweek 24
Change from baseline in fasting plasma glucose (FPG)Baseline, Week 24 and Week 52
Change from baseline in fasting insulinBaseline, Week 24 and Week 52
Change from baseline in lipid panelBaseline, Week 24 and Week 52
Change from baseline in 2-hour postprandial blood glucoseBaseline, Week 24 and Week 52
Change from baseline in 7-point self-monitored blood glucoseBaseline, Week 24 and Week 52
Change from baseline in HOMA-IRBaseline, Week 24 and Week 52
Change from baseline in HOMA-βBaseline, Week 24 and Week 52
Change from baseline in body weightBaseline, Week 24 and Week 52
Change from baseline in waist circumferenceBaseline, Week 24 and Week 52
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
75 Years
Results

Results

No results posted on ClinicalTrials.gov as of 2 Oct 2026.

Sources

  1. 1A Phase 3, Multi-center, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of XW003 in Patients With T2DM Inadequately Controlled by Diet and Exercise AloneClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026

Found an error? Report a correction.